| INTRODUCTION
Haemophilia B is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor IX. 1 Severe forms of haemophilia B present in early life, at circumcision, or with joint and soft tissue bleeds when the child becomes mobile. Mild cases may present following haemostatic challenges such as surgery or trauma. Internal bleeding may occur anywhere and bleeding into joints is common. 2 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Haemophilia B is treated by infusion of FIX concentrate. Despite substantial improvements in the safety of plasma-derived coagulation factor concentrates recombinant products are currently considered to be optimum treatment. 3 Several recombinant versions of FIX have been marketed for treatment of haemophilia B 2 including standard half-life products and extended half-life products.
Trenonacog alfa (IB1001) is a standard half-life rFIX produced in a genetically engineered Chinese hamster ovary (CHO) cell line with no exogenous materials of human or animal origin used in the manufacture, purification, or formulation of the final product. The primary amino acid sequence of IB1001 contains a threonine at residue 148, in contrast to other available conventional half-life recombinant FIX products that have an alanine at that position. 4 The manufacturing process includes three independent viral removal/inactivation steps: solvent/detergent treatment, a chromatographic step and nanofiltration.
A Phase 3 controlled, multicentre study was designed to evaluate PK non-inferiority of IB1001 to a comparator standard half-life rFIX, 
| MATERIAL AND METHODS

| Study design
The study included a PK Phase that was a randomized, double-blinded cross-over comparison of IB1001 to a marketed rFIX comparator (nonacog alfa). Following a 5-day wash out period, subjects received 75 ± 5 IU/kg of the first treatment after which there was another 5-day wash out period before receiving the second treatment. There was also a repeat open-label, uncontrolled PK phase in a subset of patients that participated in the initial PK Phase. After at least 3 months of receiving IB1001, these subjects received an infusion of 75 ± 5 IU/kg of IB1001 prior to PK assessment.
The study also consisted of an open-label Treatment Phase in which patients received IB1001 either as prophylaxis or ondemand, with a goal of acquiring 50 exposure days (ED) for prophylaxis patients or 6 months on study for on-demand patients.
Patients from the PK Phase could transition into the Treatment All patients provided informed consent prior to enrolment.
| Patient population
Eligible subjects included immunocompetent adolescents and adults (≥12 years of age) with documented severe (FIX activity <1 IU/dL) or moderately severe (FIX activity ≤2 IU/dL) haemophilia B, who had previously been treated with a FIX concentrate for at least 150 ED with no history of FIX inhibitors. On a country-specific basis, subjects <12 years of age were able to enter the study at the treatment phase.
On-demand patients had a minimum of 3 bleeds requiring treatment within 6 months prior to enrolment or 6 bleeds over the preceding 12 months; subjects on prophylaxis had to have this bleeding pattern prior to starting prophylaxis.
| Pharmacokinetic assessments
The primary objective of the PK Phase was to evaluate PK noninferiority of IB1001 to marketed standard half-life rFIX comparator (nonacog alfa). Factor IX activity levels using a one-stage clotting assay at a central laboratory were the basis for all PK parameter computations. Samples were taken pre-infusion and at the following time 
| Haemostatic efficacy
The haemostatic efficacy of IB1001 was evaluated by calculation of annualized bleed rate (ABR) for prophylaxis subjects and the number of infusions used to treat a bleed and overall rating of efficacy by subjects and investigators or surgeons (Table 1 ). Compliance to prophylactic regimen was calculated as the total number of IB1001 infusions administered, divided by the total expected number of IB1001 infusions, multiplied by 100. Investigator efficacy assessments were performed every 3 months.
| Perioperative haemostatic efficacy
The ability of IB1001 to provide adequate haemostasis during major surgeries was evaluated in the surgery sub-study. Blood loss at time of surgery and at 12 and 24 hours postsurgery were used to evaluate haemostatic efficacy of IB1001.
| Immunogenicity
Testing for FIX inhibitors was performed using a modified Nijmegen 
| Safety assessments
Safety was evaluated through reports of adverse events (AEs), haematology, blood chemistry, physical examinations and vital signs at each study visit. The same safety assessments were conducted in study subjects that transitioned to modified IB1001 (ie, study drug manufactured with a modified process to reduce host cell proteins).
| Statistical analysis
A comparison of IB1001 and nonacog alfa was based on two-sided 90% confidence interval (CI) for the AUC 0-∞ ratio of IB1001 over nonacog alfa (calculated on a log scale and then untransformed). The within-group standard deviation was determined using the pooled result for the 2 groups. Non-inferiority of IB1001 compared to nonacog alfa was declared if the lower bound of the 90% CI for the ratio of AUC 0-∞ for IB1001/nonacog alfa was >0.80. All other PK parameters between IB1001 and nonacog alfa were reported as descriptive statistics. PK data from this study has been published previously; 6 however, a different software (WinNonlin) was used to derive the PK parameters for this manuscript and an additional subject was included in repeat PK analysis. The ABR was calculated as: (number of bleeding episodes × 12)/(observed treatment period in months).
Since subjects were allowed to switch treatment regimens while on study, the efficacy analysis is based on the actual regimen. Effective Each bleeding episode treated in the interval was evaluated by the subject as either "excellent" or "good" at the majority of time points
Partially effective Bleeding episodes treated in the interval were evaluated as either "excellent", "good", or "fair" at the majority of time points; or 1 bleeding episode received an evaluation of "poor" at the majority of time points
Not effective More than one-third of bleeding episodes during the interval were evaluated as "poor" at the majority of time points 
| Study patient population
A total of 76 subjects were enrolled and received at least one infusion of IB1001 (Figure 1 ). Patient demography is presented in Table 2 .
The mean age was 30.5 years (median: 26; min, max: 7, 64). There were 3 subjects <12 years of age who received waivers to enrol in the treatment phase of the study. Most of the subjects were severe (14.5%) or moderately severe (81.6%) haemophilia B males. Median number of bleeding episodes within 6 months prior to enrolment was 1.0 (min, max: 0.0, 21.0) and the majority of subjects had arthropathy and target joints at screening. All subjects were treated with FIX replacement therapy prior to enrolment. There were 32 subjects that completed the PK Phase and following completion of the PK Phase, 29 of those subjects continued into the Treatment Phase (14 of these subjects underwent a repeat PK evaluation), while 41 subjects directly entered the Treatment Phase after an initial recovery assessment. At the start of Treatment Phase, 58 subjects elected prophylaxis and 9 subjects chose an on-demand regimen. For surgical sub-study, there were 16 subjects that underwent 19 major surgeries.
| Pharmacokinetic parameters
The lower bound 90% CI for ratio of AUC 0-∞ for IB1001/nonacog alfa was 0.89 demonstrating that the primary PK endpoint criterion of >0.80 was met. Other PK parameters between the two rFIX products were comparable (Table S1) . The repeat PK analysis demonstrated the stability of initial PK parameters during long-term exposure (median:
5.8 months; min, max: 3.1, 18 months) to IB1001 (Table S1 ).
| Haemostatic efficacy
Most of the subjects (37/61) who treated prophylactically in the Treatment/Continuation phases of the study fulfilled the criteria for secondary or tertiary prophylaxis as defined in the WFH guidelines. 4 However, subjects were allowed to switch regimens at discretion of the investigator and the subject; therefore, the analysis of efficacy includes data based on the actual treatment regimen followed.
In total, there were 61 subjects who received prophylaxis and 12 subjects who received on-demand regimen. Compliance to prophylactic treatment was 88% (median; Table 3 ). The summary of IB1001 treatment and ABR for prophylaxis and on-demand cohorts is presented in Table 4 . The mean ± SD duration of treatment for prophylaxis subjects was 17.9 ± 9.6 months (median: Baseline FIX activity (% FIX activity) n (%) <1% 11 (14.5)
1-2% 62 (81.6) >2% 3 a (3.9) a 3 subjects had FIX activity >2% at baseline after the wash-out period, however all 3 subjects in their medical history had records of FIX activity <2%, as well as symptoms consistent with severe form of haemophilia B, therefore these 3 subjects were deemed eligible for study enrollment.
(4.7%) that were predominantly related to trauma, target joints, or muscle bleeds, 5 or more infusions were required.
Haemostatic efficacy at bleed resolution was rated by the subjects as "excellent" or "good" in 84% of all treated bleeds. Overall, IB1001
haemostatic efficacy was rated as "effective" 92% of the times by the investigators, with 8% rated as "partially effective." None of the investigator ratings were reported as "not effective."
| Perioperative haemostatic efficacy
Surgery sub-study involved 16 subjects who underwent 19 evalu- ). Blood loss at the time of surgery was rated by the surgeon as "expected" (n = 6) or "less than expected" (n = 13), while at 12 and 24 hours postsurgery IB1001 was rated by the surgeon as "superior"
(n = 7) or "adequate" (n = 12) in controlling haemostasis. There were no transfusion requirements during the surgical procedures (Table 4) .
| Safety
IB1001 appeared well tolerated in all 76 study subjects exposed.
There were no deaths, severe allergic reactions, anaphylaxis, thromboembolic events or related serious adverse events (SAEs). A total of 444 AEs were reported by 57/76 subjects (75%), including 15 AEs in 7 subjects (9%) that were considered related to IB1001 treatment or adverse drug reactions (ADRs, Table 5 ). The most common ADR was headache [5 events in 2 subjects (2.6%)]. None of the subjects developed FIX inhibitors during the study, while 16/77 (21%) subjects developed non-neutralizing FIX antibodies after screening. After receiving IB1001, 68 subjects have been tested for anti-CHOP reactivity; 20 subjects (29%) seroconverted (developed persistent anti-CHOP reactivity), 37 subjects (54%) remained negative, while 11 subjects (16%) were considered indeterminate (2 subjects were positive at screening, 5 subjects had persistent non-specific antibody binding, 3 subjects had an isolated positive test result and one subject had no sufficient follow-up samples). There were no safety concerns related to development of non-neutralizing FIX antibodies or anti-CHOP antibodies. After at least 12 months of treatment with modified IB1001, there were no new seroconversions in previously anti-CHOP negative subjects (n = 10) or in subjects (n = 3) with indeterminate assay results (ie, reactive for non-specific assay control). Two subjects with anti-CHOP titres demonstrated negative anti-CHOP results after ≥12 months of modified IB1001 treatment, while the other 2 subjects had stable titres (Table S2 ).
| DISCUSSION
This was the first clinical trial with IB1001 (trenonacog alfa), a standard half-life rFIX. The results of the PK Phase demonstrated IB1001
PK non-inferiority to the comparator rFIX, and IB1001 incremental recovery of 0.98 ± 0.21 IU/dL.
Prophylactic treatment and in particular early prophylaxis has been associated with reduction in bleeding episodes. 7, 8 In this clinical trial, 61 subjects received routine prophylaxis (median duration: 16.2 months), of which 19 subjects (31%) reported no bleeding episodes. In addition, there were 12 on-demand subjects (median duration: 16.1 months)
in the study. The dose ranges used to treat bleeding episodes in this study (50-100 IU/kg) are similar to the dosing recommendations for As expected, the ABR of prophylaxis cohort (median: 1.52) was lower when compared to the ABR of on-demand cohort (median: 16.10).
This is consistent with the previously published data on rFIX therapy. 9, 10 The percentage of subjects with baseline FIX levels 1-2 IU/dL is 81%, which is higher than in other studies, although all subjects in this study had a severe bleeding phenotype prior to study entry.
Haemostatic efficacy of IB1001 was evaluated in the Treatment and Continuation phases of the study. Of the 508 bleeding episodes, regardless of treatment regimen or type of bleeding episode (ie, spontaneous or due to trauma) where IB1001 efficacy was rated by subjects, the efficacy was considered "good" or "excellent" 84% of the time. The majority of bleeds (84%) were resolved with one to two IB1001 infusions, similar to results derived from studies with other standard half-life rFIX products. However, all ratings of haemostasis with IB1001 at the time of surgery were at least "expected" and all ratings postsurgery were at least "adequate" when compared to similar procedures in non-haemophilic patients. This is supported by the lack of transfusion requirements during the procedures.
IB1001 was well tolerated as there were no reports of deaths, allergic reactions, anaphylaxis, thromboembolic events or related SAEs.
The most common ADR was headache (2.6% of subjects). There were no reports of FIX inhibitors at any point during the study. Some subjects (n = 10). Two out of 4 subjects with anti-CHOP titres reverted to anti-CHOP negative status, while the other 2 subjects had stable titres.
Overall, these results may indicate that the anti-CHOP immunogenicity potential of modified IB1001 has been reduced with the addition of the validated step to IB1001 manufacturing process.
| CONCLUSION
The non-inferior PK profile of IB1001 to nonacog alfa, the generally positive assessment of control and treatment of breakthrough and other bleeding episodes during the Treatment/Continuation phase by both patients and investigators, and the uniformly positive assessments of haemostatic adequacy or superiority of IB1001 for perioperative management of major surgeries, provide strong evidence of the efficacy of IB1001 for the control, prevention, and reduction in bleeding in subjects with haemophilia B. The lack of significant safety findings, specifically lack of any detected FIX inhibitors and all other serious class specific adverse events provide support that the safety profile of IB1001 is acceptable for treatment of subjects with haemophilia B. T A B L E 5 Summary of adverse drug reactions (ADRs)
